

**Adverse Event profiles of Antiseizure Medications and the Impact of Coadministration
on Drug Tolerability in Adults with Epilepsy**

Laurent M. Willems^{1,2,3}; Milena van der Goten¹; Felix von Podewils⁴; Susanne Knake^{3,5,6};
Stjepana Kovac^{7,8}; Johann Philipp Zöllner^{1,2,3}; Felix Rosenow^{1,2,3}; Adam Strzelczyk^{1,2,3,6}

¹ Epilepsy Center Frankfurt Rhine-Main, Goethe-University and University Hospital Frankfurt,
Frankfurt am Main, Germany.

² Department of Neurology, Goethe-University and University Hospital Frankfurt,
Frankfurt am Main, Germany.

³ LOEWE Center for Personalized Translational Epilepsy Research (CEPTeR),
Goethe-University Frankfurt, Frankfurt am Main, Germany.

⁴ Department of Neurology, University Hospital Greifswald, Greifswald, Germany.

⁵ Epilepsy Center Hessen, Philipps-University Marburg, Marburg, Germany.

⁶ Department of Neurology, Philipps-University Marburg, Marburg, Germany.

⁷ Epilepsy Center Münster-Osnabrück, Westfälische Wilhelms-University, Münster, Germany.

⁸ Department of Neurology, Westfälische Wilhelms-University, Münster, Germany.

Correspondence to:

Prof. Dr. med. Adam Strzelczyk
Epilepsy Center Frankfurt Rhine-Main
Department of Neurology
Goethe-University Frankfurt
Schleusenweg 2-16
60528 Frankfurt am Main
Germany
email: strzelczyk@med.uni-frankfurt.de

Supplementary Table 1: Characteristics of adverse event and depression metrics

	Provided by % (<i>n</i>)	Mean	SD	Median	Range
Liverpool Adverse Events Profile (LAEP)	98.8 (480)	38.2	12.1	38.0	19.0–72.0
Hospital Anxiety and Depression Scale (HADS)	96.9 (471)	12.7	6.5	11.0	2.0–35.0
Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)	95.1 (462)	11.3	4.3	10.0	6.0–24.0

SD, standard deviation.